Key Points
- Altimmune Director Jerome Benedict Durso purchased 12,500 shares on December 22 at an average price of $4.13, a $51,625 transaction disclosed in an SEC filing.
- ALT opened at $4.14 with a market cap of $431.97 million and a 52-week range of $2.90–$8.25; analysts hold a consensus Moderate Buy rating with an average price target of $16.83.
- Institutional investors own 78.05% of the company, with large increases in holdings from Vanguard and Two Sigma in recent quarters.
Altimmune, Inc. (NASDAQ:ALT - Get Free Report) Director Jerome Benedict Durso purchased 12,500 shares of the business's stock in a transaction dated Monday, December 22nd. The stock was bought at an average price of $4.13 per share, with a total value of $51,625.00. Following the acquisition, the director directly owned 12,500 shares in the company, valued at approximately $51,625. This represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.
Altimmune Stock Up 6.2%
ALT stock opened at $4.14 on Tuesday. The company has a current ratio of 17.18, a quick ratio of 17.18 and a debt-to-equity ratio of 0.08. The company's 50-day moving average price is $4.52 and its 200 day moving average price is $4.39. Altimmune, Inc. has a 52 week low of $2.90 and a 52 week high of $8.25. The company has a market cap of $431.97 million, a P/E ratio of -3.87 and a beta of -0.03.
Altimmune (NASDAQ:ALT - Get Free Report) last issued its earnings results on Thursday, November 6th. The company reported ($0.21) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.29) by $0.08. The company had revenue of $0.01 million during the quarter, compared to analysts' expectations of $0.00 million. Altimmune had a negative net margin of 419,575.00% and a negative return on equity of 54.79%. On average, research analysts expect that Altimmune, Inc. will post -1.35 earnings per share for the current fiscal year.
Wall Street Analyst Weigh In
ALT has been the topic of a number of research analyst reports. Weiss Ratings reiterated a "sell (d-)" rating on shares of Altimmune in a research report on Monday, December 15th. Citigroup reiterated a "market outperform" rating on shares of Altimmune in a research report on Wednesday, November 12th. Citizens Jmp lowered their price objective on shares of Altimmune from $15.00 to $14.00 and set a "market outperform" rating on the stock in a research note on Friday, November 7th. Finally, HC Wainwright restated a "buy" rating and set a $12.00 target price on shares of Altimmune in a research report on Monday, October 20th. Seven equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $16.83.
Read Our Latest Report on ALT
Institutional Trading of Altimmune
A number of large investors have recently made changes to their positions in ALT. Vanguard Group Inc. increased its position in Altimmune by 23.3% during the 3rd quarter. Vanguard Group Inc. now owns 6,373,638 shares of the company's stock worth $24,029,000 after purchasing an additional 1,206,514 shares in the last quarter. Two Sigma Investments LP boosted its stake in shares of Altimmune by 356.6% during the 3rd quarter. Two Sigma Investments LP now owns 1,996,848 shares of the company's stock worth $7,528,000 after purchasing an additional 1,559,562 shares during the last quarter. Geode Capital Management LLC grew its holdings in shares of Altimmune by 13.4% during the second quarter. Geode Capital Management LLC now owns 1,934,880 shares of the company's stock worth $7,489,000 after buying an additional 228,995 shares in the last quarter. Federated Hermes Inc. grew its holdings in shares of Altimmune by 387.7% during the second quarter. Federated Hermes Inc. now owns 915,458 shares of the company's stock worth $3,543,000 after buying an additional 727,731 shares in the last quarter. Finally, Bank of America Corp DE raised its position in shares of Altimmune by 155.2% in the second quarter. Bank of America Corp DE now owns 716,019 shares of the company's stock valued at $2,771,000 after buying an additional 435,467 shares during the last quarter. Institutional investors and hedge funds own 78.05% of the company's stock.
Altimmune Company Profile
(
Get Free Report)
Altimmune, Inc is a clinical-stage biopharmaceutical company headquartered in Gaithersburg, Maryland, dedicated to the development of vaccines and immunotherapeutics. The company leverages proprietary technology platforms to create intranasal vaccine candidates and novel therapies targeting liver diseases and metabolic disorders. Altimmune's approach emphasizes the stimulation of both systemic and mucosal immune responses to address unmet medical needs in infectious and chronic conditions.
Among its lead programs, NasoVAX is an investigational intranasal influenza vaccine designed to provide broad, long-lasting protection through a single, non-invasive dose.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
